[{"month":"12","tmp":{"name":"Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)","legal_code_url":"https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode","short":"CC BY-NC-ND (4.0)","image":"/images/cc_by_nc_nd.png"},"user_id":"4359f0d1-fa6c-11eb-b949-802e58b17ae8","doi":"10.1016/j.immuni.2022.10.001","pmid":1,"ddc":["570"],"abstract":[{"lang":"eng","text":"Intravascular neutrophils and platelets collaborate in maintaining host integrity, but their interaction can also trigger thrombotic complications. We report here that cooperation between neutrophil and platelet lineages extends to the earliest stages of platelet formation by megakaryocytes in the bone marrow. Using intravital microscopy, we show that neutrophils “plucked” intravascular megakaryocyte extensions, termed proplatelets, to control platelet production. Following CXCR4-CXCL12-dependent migration towards perisinusoidal megakaryocytes, plucking neutrophils actively pulled on proplatelets and triggered myosin light chain and extracellular-signal-regulated kinase activation through reactive oxygen species. By these mechanisms, neutrophils accelerate proplatelet growth and facilitate continuous release of platelets in steady state. Following myocardial infarction, plucking neutrophils drove excessive release of young, reticulated platelets and boosted the risk of recurrent ischemia. Ablation of neutrophil plucking normalized thrombopoiesis and reduced recurrent thrombosis after myocardial infarction and thrombus burden in venous thrombosis. We establish neutrophil plucking as a target to reduce thromboischemic events."}],"publication_status":"published","date_published":"2022-12-13T00:00:00Z","status":"public","day":"13","license":"https://creativecommons.org/licenses/by-nc-nd/4.0/","file":[{"creator":"dernst","access_level":"open_access","date_updated":"2023-01-23T10:18:48Z","content_type":"application/pdf","relation":"main_file","checksum":"073267a9c0ad9f85a650053bc7b23777","date_created":"2023-01-23T10:18:48Z","file_id":"12341","success":1,"file_name":"2022_Immunity_Petzold.pdf","file_size":5299475}],"date_updated":"2025-04-14T07:43:16Z","oa_version":"Published Version","issue":"12","ec_funded":1,"oa":1,"language":[{"iso":"eng"}],"article_processing_charge":"No","date_created":"2023-01-12T11:56:54Z","acknowledgement":"We thank Coung Kieu and Dominik van den Heuvel for excellent technical assistance. This work was supported by the German Research Foundation (PE2704/2-1, PE2704/3-1 to T.P., SFB 1123-project B06 to S.M., SFB1525 project A07 to D.S, TRR 332 project A7 to C.S., PO 2247/2-1 to A.P., SFB1116-project B11 to A.P. and B12 to M.K.), LMU Munich’s Institutional\r\nStrategy LMUexcellent within the framework of the German Excellence Initiative (No. 806 32 006 to T.P.), and by the German Centre for Cardiovascular Research (DZHK) to T.P. (Postdoc Start-up grant No. 100378833). This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. 833440 to S.M.). F.G. received funding from the European Union’s\r\nHorizon 2020 research and innovation program under the Marie Sk1odowska-Curie grant agreement no. 747687. A.H. was funded by RTI2018-095497-B-I00 from Ministerio de Ciencia e Innovacio´ n (MICINN), HR17_00527 from Fundacion La Caixa, and Transatlantic Network of Excellence (TNE-18CVD04) from the Leducq Foundation. The CNIC is supported by the MICINN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S). A.P. was supported by the Forschungskommission of the Medical Faculty of the Heinrich-Heine-Universität Düsseldorf (No. 18-2019 to A.P.). C.G. was supported by the Helmholtz Alliance ‘Aging and Metabolic Programming, AMPro,’ by the German Federal\r\nMinistry of Education and Research to the German Center for Diabetes Research (DZD), and by the Bavarian State Ministry of Health and Care through the research project DigiMed Bayern.","publication_identifier":{"issn":["1074-7613"]},"department":[{"_id":"MiSi"}],"page":"2285-2299.e7","volume":55,"external_id":{"isi":["000922019600003"],"pmid":["36272416"]},"article_type":"original","title":"Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease","project":[{"name":"Mechanical Adaptation of Lamellipodial Actin Networks in Migrating Cells","_id":"260AA4E2-B435-11E9-9278-68D0E5697425","grant_number":"747687","call_identifier":"H2020"}],"publication":"Immunity","year":"2022","intvolume":"        55","publisher":"Elsevier","isi":1,"type":"journal_article","quality_controlled":"1","scopus_import":"1","has_accepted_license":"1","keyword":["Infectious Diseases","Immunology","Immunology and Allergy"],"citation":{"chicago":"Petzold, Tobias, Zhe Zhang, Iván Ballesteros, Inas Saleh, Amin Polzin, Manuela Thienel, Lulu Liu, et al. “Neutrophil ‘Plucking’ on Megakaryocytes Drives Platelet Production and Boosts Cardiovascular Disease.” <i>Immunity</i>. Elsevier, 2022. <a href=\"https://doi.org/10.1016/j.immuni.2022.10.001\">https://doi.org/10.1016/j.immuni.2022.10.001</a>.","apa":"Petzold, T., Zhang, Z., Ballesteros, I., Saleh, I., Polzin, A., Thienel, M., … Massberg, S. (2022). Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease. <i>Immunity</i>. Elsevier. <a href=\"https://doi.org/10.1016/j.immuni.2022.10.001\">https://doi.org/10.1016/j.immuni.2022.10.001</a>","short":"T. Petzold, Z. Zhang, I. Ballesteros, I. Saleh, A. Polzin, M. Thienel, L. Liu, Q. Ul Ain, V. Ehreiser, C. Weber, B. Kilani, P. Mertsch, J. Götschke, S. Cremer, W. Fu, M. Lorenz, H. Ishikawa-Ankerhold, E. Raatz, S. El-Nemr, A. Görlach, E. Marhuenda, K. Stark, J. Pircher, D. Stegner, C. Gieger, M. Schmidt-Supprian, F.R. Gärtner, I. Almendros, M. Kelm, C. Schulz, A. Hidalgo, S. Massberg, Immunity 55 (2022) 2285–2299.e7.","ama":"Petzold T, Zhang Z, Ballesteros I, et al. Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease. <i>Immunity</i>. 2022;55(12):2285-2299.e7. doi:<a href=\"https://doi.org/10.1016/j.immuni.2022.10.001\">10.1016/j.immuni.2022.10.001</a>","ieee":"T. Petzold <i>et al.</i>, “Neutrophil ‘plucking’ on megakaryocytes drives platelet production and boosts cardiovascular disease,” <i>Immunity</i>, vol. 55, no. 12. Elsevier, p. 2285–2299.e7, 2022.","mla":"Petzold, Tobias, et al. “Neutrophil ‘Plucking’ on Megakaryocytes Drives Platelet Production and Boosts Cardiovascular Disease.” <i>Immunity</i>, vol. 55, no. 12, Elsevier, 2022, p. 2285–2299.e7, doi:<a href=\"https://doi.org/10.1016/j.immuni.2022.10.001\">10.1016/j.immuni.2022.10.001</a>.","ista":"Petzold T, Zhang Z, Ballesteros I, Saleh I, Polzin A, Thienel M, Liu L, Ul Ain Q, Ehreiser V, Weber C, Kilani B, Mertsch P, Götschke J, Cremer S, Fu W, Lorenz M, Ishikawa-Ankerhold H, Raatz E, El-Nemr S, Görlach A, Marhuenda E, Stark K, Pircher J, Stegner D, Gieger C, Schmidt-Supprian M, Gärtner FR, Almendros I, Kelm M, Schulz C, Hidalgo A, Massberg S. 2022. Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease. Immunity. 55(12), 2285–2299.e7."},"file_date_updated":"2023-01-23T10:18:48Z","_id":"12119","author":[{"full_name":"Petzold, Tobias","first_name":"Tobias","last_name":"Petzold"},{"first_name":"Zhe","last_name":"Zhang","full_name":"Zhang, Zhe"},{"first_name":"Iván","last_name":"Ballesteros","full_name":"Ballesteros, Iván"},{"full_name":"Saleh, Inas","first_name":"Inas","last_name":"Saleh"},{"last_name":"Polzin","first_name":"Amin","full_name":"Polzin, Amin"},{"first_name":"Manuela","last_name":"Thienel","full_name":"Thienel, Manuela"},{"first_name":"Lulu","last_name":"Liu","full_name":"Liu, Lulu"},{"first_name":"Qurrat","last_name":"Ul Ain","full_name":"Ul Ain, Qurrat"},{"full_name":"Ehreiser, Vincent","first_name":"Vincent","last_name":"Ehreiser"},{"first_name":"Christian","last_name":"Weber","full_name":"Weber, Christian"},{"full_name":"Kilani, Badr","last_name":"Kilani","first_name":"Badr"},{"last_name":"Mertsch","first_name":"Pontus","full_name":"Mertsch, Pontus"},{"last_name":"Götschke","first_name":"Jeremias","full_name":"Götschke, Jeremias"},{"first_name":"Sophie","last_name":"Cremer","full_name":"Cremer, Sophie"},{"full_name":"Fu, Wenwen","first_name":"Wenwen","last_name":"Fu"},{"last_name":"Lorenz","first_name":"Michael","full_name":"Lorenz, Michael"},{"first_name":"Hellen","last_name":"Ishikawa-Ankerhold","full_name":"Ishikawa-Ankerhold, Hellen"},{"full_name":"Raatz, Elisabeth","first_name":"Elisabeth","last_name":"Raatz"},{"last_name":"El-Nemr","first_name":"Shaza","full_name":"El-Nemr, Shaza"},{"full_name":"Görlach, Agnes","last_name":"Görlach","first_name":"Agnes"},{"full_name":"Marhuenda, Esther","first_name":"Esther","last_name":"Marhuenda"},{"first_name":"Konstantin","last_name":"Stark","full_name":"Stark, Konstantin"},{"full_name":"Pircher, Joachim","last_name":"Pircher","first_name":"Joachim"},{"full_name":"Stegner, David","first_name":"David","last_name":"Stegner"},{"full_name":"Gieger, Christian","first_name":"Christian","last_name":"Gieger"},{"full_name":"Schmidt-Supprian, Marc","first_name":"Marc","last_name":"Schmidt-Supprian"},{"first_name":"Florian R","id":"397A88EE-F248-11E8-B48F-1D18A9856A87","last_name":"Gärtner","orcid":"0000-0001-6120-3723","full_name":"Gärtner, Florian R"},{"first_name":"Isaac","last_name":"Almendros","full_name":"Almendros, Isaac"},{"full_name":"Kelm, Malte","first_name":"Malte","last_name":"Kelm"},{"full_name":"Schulz, Christian","last_name":"Schulz","first_name":"Christian"},{"full_name":"Hidalgo, Andrés","last_name":"Hidalgo","first_name":"Andrés"},{"last_name":"Massberg","first_name":"Steffen","full_name":"Massberg, Steffen"}]},{"status":"public","date_published":"2022-09-16T00:00:00Z","ddc":["570"],"abstract":[{"lang":"eng","text":"The COVID−19 pandemic not only resulted in a global crisis, but also accelerated vaccine development and antibody discovery. Herein we report a synthetic humanized VHH library development pipeline for nanomolar-range affinity VHH binders to SARS-CoV-2 variants of concern (VoC) receptor binding domains (RBD) isolation. Trinucleotide-based randomization of CDRs by Kunkel mutagenesis with the subsequent rolling-cycle amplification resulted in more than 10<jats:sup>11</jats:sup> diverse phage display library in a manageable for a single person number of electroporation reactions. We identified a number of nanomolar-range affinity VHH binders to SARS-CoV-2 variants of concern (VoC) receptor binding domains (RBD) by screening a novel synthetic humanized antibody library. In order to explore the most robust and fast method for affinity improvement, we performed affinity maturation by CDR1 and CDR2 shuffling and avidity engineering by multivalent trimeric VHH fusion protein construction. As a result, H7-Fc and G12x3-Fc binders were developed with the affinities in nM and pM range respectively. Importantly, these affinities are weakly influenced by most of SARS-CoV-2 VoC mutations and they retain moderate binding to BA.4\\5. The plaque reduction neutralization test (PRNT) resulted in IC50 = 100 ng\\ml and 9.6 ng\\ml for H7-Fc and G12x3-Fc antibodies, respectively, for the emerging Omicron BA.1 variant. Therefore, these VHH could expand the present landscape of SARS-CoV-2 neutralization binders with the therapeutic potential for present and future SARS-CoV-2 variants."}],"publication_status":"published","user_id":"2DF688A6-F248-11E8-B48F-1D18A9856A87","doi":"10.3389/fimmu.2022.965446","pmid":1,"month":"09","tmp":{"short":"CC BY (4.0)","image":"/images/cc_by.png","name":"Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)","legal_code_url":"https://creativecommons.org/licenses/by/4.0/legalcode"},"oa":1,"language":[{"iso":"eng"}],"date_updated":"2025-06-11T13:42:26Z","oa_version":"Published Version","file":[{"relation":"main_file","content_type":"application/pdf","date_updated":"2023-01-30T09:22:26Z","access_level":"open_access","creator":"dernst","file_name":"2022_FrontiersImmunology_Dormeshkin.pdf","file_size":5695892,"success":1,"file_id":"12443","date_created":"2023-01-30T09:22:26Z","checksum":"f8f5d8110710033d0532e7e08bf9dad4"}],"day":"16","publication":"Frontiers in Immunology","year":"2022","volume":13,"external_id":{"pmid":["36189235"],"isi":["000862479100001"]},"title":"Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library","article_type":"original","department":[{"_id":"LeSa"}],"publication_identifier":{"issn":["1664-3224"]},"article_processing_charge":"No","acknowledgement":"The authors declare that this study received funding from Immunofusion. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.","date_created":"2023-01-16T09:56:57Z","_id":"12252","file_date_updated":"2023-01-30T09:22:26Z","author":[{"full_name":"Dormeshkin, Dmitri","first_name":"Dmitri","last_name":"Dormeshkin"},{"last_name":"Shapira","first_name":"Michail","full_name":"Shapira, Michail"},{"full_name":"Dubovik, Simon","last_name":"Dubovik","first_name":"Simon"},{"first_name":"Anton","id":"4968f7ad-eb97-11eb-a6c2-8ed382e8912c","last_name":"Kavaleuski","orcid":"0000-0003-2091-526X","full_name":"Kavaleuski, Anton"},{"full_name":"Katsin, Mikalai","first_name":"Mikalai","last_name":"Katsin"},{"full_name":"Migas, Alexandr","first_name":"Alexandr","last_name":"Migas"},{"last_name":"Meleshko","first_name":"Alexander","full_name":"Meleshko, Alexander"},{"first_name":"Sergei","last_name":"Semyonov","full_name":"Semyonov, Sergei"}],"keyword":["Immunology","Immunology and Allergy","COVID-19","SARS-CoV-2","synthetic library","RBD","neutralization nanobody","VHH"],"citation":{"chicago":"Dormeshkin, Dmitri, Michail Shapira, Simon Dubovik, Anton Kavaleuski, Mikalai Katsin, Alexandr Migas, Alexander Meleshko, and Sergei Semyonov. “Isolation of an Escape-Resistant SARS-CoV-2 Neutralizing Nanobody from a Novel Synthetic Nanobody Library.” <i>Frontiers in Immunology</i>. Frontiers Media, 2022. <a href=\"https://doi.org/10.3389/fimmu.2022.965446\">https://doi.org/10.3389/fimmu.2022.965446</a>.","apa":"Dormeshkin, D., Shapira, M., Dubovik, S., Kavaleuski, A., Katsin, M., Migas, A., … Semyonov, S. (2022). Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library. <i>Frontiers in Immunology</i>. Frontiers Media. <a href=\"https://doi.org/10.3389/fimmu.2022.965446\">https://doi.org/10.3389/fimmu.2022.965446</a>","short":"D. Dormeshkin, M. Shapira, S. Dubovik, A. Kavaleuski, M. Katsin, A. Migas, A. Meleshko, S. Semyonov, Frontiers in Immunology 13 (2022).","ama":"Dormeshkin D, Shapira M, Dubovik S, et al. Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library. <i>Frontiers in Immunology</i>. 2022;13. doi:<a href=\"https://doi.org/10.3389/fimmu.2022.965446\">10.3389/fimmu.2022.965446</a>","mla":"Dormeshkin, Dmitri, et al. “Isolation of an Escape-Resistant SARS-CoV-2 Neutralizing Nanobody from a Novel Synthetic Nanobody Library.” <i>Frontiers in Immunology</i>, vol. 13, 965446, Frontiers Media, 2022, doi:<a href=\"https://doi.org/10.3389/fimmu.2022.965446\">10.3389/fimmu.2022.965446</a>.","ieee":"D. Dormeshkin <i>et al.</i>, “Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library,” <i>Frontiers in Immunology</i>, vol. 13. Frontiers Media, 2022.","ista":"Dormeshkin D, Shapira M, Dubovik S, Kavaleuski A, Katsin M, Migas A, Meleshko A, Semyonov S. 2022. Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library. Frontiers in Immunology. 13, 965446."},"scopus_import":"1","article_number":"965446","quality_controlled":"1","has_accepted_license":"1","isi":1,"type":"journal_article","publisher":"Frontiers Media","intvolume":"        13"},{"file":[{"success":1,"file_name":"2021_Allergy_Pranger.pdf","file_size":626081,"checksum":"9526f9554112fc027c9f7fa540c488cd","date_created":"2022-03-08T11:23:16Z","file_id":"10837","content_type":"application/pdf","relation":"main_file","creator":"dernst","access_level":"open_access","date_updated":"2022-03-08T11:23:16Z"}],"day":"01","language":[{"iso":"eng"}],"oa":1,"issue":"5","date_updated":"2023-09-05T15:58:53Z","oa_version":"Published Version","doi":"10.1111/all.14604","pmid":1,"user_id":"c635000d-4b10-11ee-a964-aac5a93f6ac1","tmp":{"short":"CC BY (4.0)","image":"/images/cc_by.png","name":"Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)","legal_code_url":"https://creativecommons.org/licenses/by/4.0/legalcode"},"month":"05","date_published":"2021-05-01T00:00:00Z","status":"public","publication_status":"published","ddc":["570"],"type":"journal_article","isi":1,"intvolume":"        76","publisher":"Wiley","author":[{"full_name":"Pranger, Christina L.","last_name":"Pranger","first_name":"Christina L."},{"full_name":"Fazekas-Singer, Judit","first_name":"Judit","last_name":"Fazekas-Singer","id":"36432834-F248-11E8-B48F-1D18A9856A87","orcid":"0000-0002-8777-3502"},{"full_name":"Köhler, Verena K.","first_name":"Verena K.","last_name":"Köhler"},{"full_name":"Pali‐Schöll, Isabella","last_name":"Pali‐Schöll","first_name":"Isabella"},{"first_name":"Alessandro","last_name":"Fiocchi","full_name":"Fiocchi, Alessandro"},{"full_name":"Karagiannis, Sophia N.","last_name":"Karagiannis","first_name":"Sophia N."},{"last_name":"Zenarruzabeitia","first_name":"Olatz","full_name":"Zenarruzabeitia, Olatz"},{"full_name":"Borrego, Francisco","last_name":"Borrego","first_name":"Francisco"},{"full_name":"Jensen‐Jarolim, Erika","first_name":"Erika","last_name":"Jensen‐Jarolim"}],"_id":"10836","file_date_updated":"2022-03-08T11:23:16Z","has_accepted_license":"1","quality_controlled":"1","scopus_import":"1","citation":{"mla":"Pranger, Christina L., et al. “PIPE‐cloned Human IgE and IgG4 Antibodies: New Tools for Investigating Cow’s Milk Allergy and Tolerance.” <i>Allergy</i>, vol. 76, no. 5, Wiley, 2021, pp. 1553–56, doi:<a href=\"https://doi.org/10.1111/all.14604\">10.1111/all.14604</a>.","ieee":"C. L. Pranger <i>et al.</i>, “PIPE‐cloned human IgE and IgG4 antibodies: New tools for investigating cow’s milk allergy and tolerance,” <i>Allergy</i>, vol. 76, no. 5. Wiley, pp. 1553–1556, 2021.","ista":"Pranger CL, Singer J, Köhler VK, Pali‐Schöll I, Fiocchi A, Karagiannis SN, Zenarruzabeitia O, Borrego F, Jensen‐Jarolim E. 2021. PIPE‐cloned human IgE and IgG4 antibodies: New tools for investigating cow’s milk allergy and tolerance. Allergy. 76(5), 1553–1556.","ama":"Pranger CL, Singer J, Köhler VK, et al. PIPE‐cloned human IgE and IgG4 antibodies: New tools for investigating cow’s milk allergy and tolerance. <i>Allergy</i>. 2021;76(5):1553-1556. doi:<a href=\"https://doi.org/10.1111/all.14604\">10.1111/all.14604</a>","apa":"Pranger, C. L., Singer, J., Köhler, V. K., Pali‐Schöll, I., Fiocchi, A., Karagiannis, S. N., … Jensen‐Jarolim, E. (2021). PIPE‐cloned human IgE and IgG4 antibodies: New tools for investigating cow’s milk allergy and tolerance. <i>Allergy</i>. Wiley. <a href=\"https://doi.org/10.1111/all.14604\">https://doi.org/10.1111/all.14604</a>","short":"C.L. Pranger, J. Singer, V.K. Köhler, I. Pali‐Schöll, A. Fiocchi, S.N. Karagiannis, O. Zenarruzabeitia, F. Borrego, E. Jensen‐Jarolim, Allergy 76 (2021) 1553–1556.","chicago":"Pranger, Christina L., Judit Singer, Verena K. Köhler, Isabella Pali‐Schöll, Alessandro Fiocchi, Sophia N. Karagiannis, Olatz Zenarruzabeitia, Francisco Borrego, and Erika Jensen‐Jarolim. “PIPE‐cloned Human IgE and IgG4 Antibodies: New Tools for Investigating Cow’s Milk Allergy and Tolerance.” <i>Allergy</i>. Wiley, 2021. <a href=\"https://doi.org/10.1111/all.14604\">https://doi.org/10.1111/all.14604</a>."},"keyword":["Immunology","Immunology and Allergy"],"department":[{"_id":"Bio"}],"acknowledgement":"This  work  was  supported  by  the  Austrian  Science  Fund  (FWF)  grants  MCCA  W1248-B30  and  SFB  F4606-B28  to  EJJ.  CP  received  a  short-term research fellowship of the European Federation of Immunological Societies  (EFIS-IL)  for  a  research  visit  at  Biocruces  Bizkaia  Health  Research  Institute,  Barakaldo,  Spain.  VKK  received  an  EFIS-IL  short-term  research  fellowship  for  a  research  visit  at  King’s  College  London.  The research was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS-BRC-1215-20006) (SNK).  The  authors  acknowledge  support  by  the  Medical  Research  Council (MR/L023091/1) (SNK); Breast Cancer Now (147; KCL-BCN-Q3)(SNK); Cancer Research UK (C30122/A11527; C30122/A15774) (SNK); Cancer  Research  UK  King's  Health  Partners  Centre  at  King's  College  London   (C604/A25135)   (SNK);   CRUK/NIHR   in   England/DoH   for   Scotland,  Wales  and  Northern  Ireland  Experimental  Cancer  Medicine  Centre  (C10355/A15587)  (SNK).  The  views  expressed  are  those  of  the  author(s)  and  not  necessarily  those  of  the  NHS,  the  NIHR  or  the  Department  of  Health.  Additionally,  this  work  was  funded  by  Instituto  de  Salud  Carlos  III  through  the  project  \"PI16/01223\"  (Co-funded  by  European Regional Development Fund; “A way to make Europe”) to FB and  by  the  Department  of  Health,  Basque  Government  through  the  project “2019111031” to OZ. OZ is recipient of a Sara Borrell 2017 post-doctoral contract “CD17/00128” funded by Instituto de Salud Carlos III (Co-funded by European Social Fund; “Investing in your future”).","date_created":"2022-03-08T11:19:05Z","article_processing_charge":"No","publication_identifier":{"eissn":["1398-9995"],"issn":["0105-4538"]},"article_type":"letter_note","title":"PIPE‐cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance","external_id":{"pmid":["32990982"],"isi":["000577708800001"]},"volume":76,"year":"2021","publication":"Allergy","page":"1553-1556"}]